Literature DB >> 30096273

Management of Small Bowel Neuroendocrine Tumors.

Aaron T Scott1, James R Howe1.   

Abstract

Small bowel neuroendocrine tumors (NETs) are increasing in incidence and are now the most common primary malignancies of the small intestine. Despite this increase, the vague presentation and slow growth of these tumors lead to long delays in diagnosis, and many patients present with metastases. Patients with metastatic small bowel NETs have a favorable disease prognosis, particularly when contrasted with other GI malignancies, and benefit from aggressive, multimodal therapy. During the past decade, the options for the diagnosis and treatment of small bowel NETs have increased considerably. This review provides a practical framework for the physician who seek to understand the epidemiology, presentation, diagnosis, and management of small bowel NETs.

Entities:  

Mesh:

Year:  2018        PMID: 30096273      PMCID: PMC6091496          DOI: 10.1200/JOP.18.00135

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.714


  60 in total

1.  Life history of the carcinoid tumor of the small intestine.

Authors:  C G MOERTEL; W G SAUER; M B DOCKERTY; A H BAGGENSTOSS
Journal:  Cancer       Date:  1961 Sep-Oct       Impact factor: 6.860

2.  A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Kristen M Stashek; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

3.  The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.

Authors:  Evangelia Skoura; Sofia Michopoulou; Mullan Mohmaduvesh; Emmanouil Panagiotidis; Mohammed Al Harbi; Christos Toumpanakis; Omar Almukhailed; Irfan Kayani; Rizwan Syed; Shaunak Navalkissoor; Peter J Ell; Martyn E Caplin; Jamshed Bomanji
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

Review 4.  Carcinoids and carcinoid syndrome.

Authors:  W Creutzfeldt; F Stöckmann
Journal:  Am J Med       Date:  1987-05-29       Impact factor: 4.965

Review 5.  Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?

Authors:  Angela Lamarca; Emma Elliott; Jorge Barriuso; Alison Backen; Mairéad G McNamara; Richard Hubner; Juan W Valle
Journal:  Cancer Treat Rev       Date:  2016-01-25       Impact factor: 12.111

6.  Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution.

Authors:  Fadi S Dahdaleh; Daniel Calva-Cerqueira; Jennifer C Carr; Junlin Liao; James J Mezhir; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2011-08-16       Impact factor: 5.344

Review 7.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

8.  Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.

Authors:  Kendall J Keck; Allen Choi; Jessica E Maxwell; Guiying Li; Thomas M O'Dorisio; Patrick Breheny; Andrew M Bellizzi; James R Howe
Journal:  Ann Surg Oncol       Date:  2017-05-30       Impact factor: 5.344

Review 9.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

10.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Authors:  James C Yao; Nicola Fazio; Simron Singh; Roberto Buzzoni; Carlo Carnaghi; Edward Wolin; Jiri Tomasek; Markus Raderer; Harald Lahner; Maurizio Voi; Lida Bubuteishvili Pacaud; Nicolas Rouyrre; Carolin Sachs; Juan W Valle; Gianfranco Delle Fave; Eric Van Cutsem; Margot Tesselaar; Yasuhiro Shimada; Do-Youn Oh; Jonathan Strosberg; Matthew H Kulke; Marianne E Pavel
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321

View more
  14 in total

Review 1.  Carcinoid Tumors: Past, Present, and Future.

Authors:  James R Howe
Journal:  Indian J Surg Oncol       Date:  2020-05-09

2.  Casting a Wider NET: Is It Crohn's or Is It Neuroendocrine Tumor?

Authors:  Yejoo Jeon; David Leung; Claire A Lis; Hanlin L Wang; Corinne Deurdulian; Mark Mandelkern; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2021-03-30       Impact factor: 3.199

3.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

Review 4.  Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues.

Authors:  Parul Agarwal; Amr Mohamed
Journal:  Curr Treat Options Oncol       Date:  2022-08-08

Review 5.  Extent of Lymph Node Dissection for Small Bowel Neuroendocrine Tumors.

Authors:  Julie Hallet; Calvin Law
Journal:  World J Surg       Date:  2020-07-31       Impact factor: 3.352

Review 6.  Role of Primary Tumor Resection for Metastatic Small Bowel Neuroendocrine Tumors.

Authors:  Julie Hallet; Calvin Law
Journal:  World J Surg       Date:  2020-08-14       Impact factor: 3.352

7.  Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment.

Authors:  Angela Lamarca; Mauro Cives; Louis de Mestier; Joakim Crona; Francesca Spada; Kjell Öberg; Marianne Pavel; Teresa Alonso-Gordoa
Journal:  World J Gastroenterol       Date:  2021-03-14       Impact factor: 5.742

8.  Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors.

Authors:  Servando Hernandez Vargas; Christie Lin; Julie Voss; Sukhen C Ghosh; Daniel M Halperin; Solmaz AghaAmiri; Hop S Tran Cao; Naruhiko Ikoma; Adam J Uselmann; Ali Azhdarinia
Journal:  J Biomed Opt       Date:  2020-12       Impact factor: 3.170

9.  Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Sarit T Kipnis; Matthew Hung; Shria Kumar; Jason M Heckert; Hwan Lee; Bonita Bennett; Michael C Soulen; Daniel A Pryma; David A Mankoff; David C Metz; Jennifer R Eads; Bryson W Katona
Journal:  JAMA Netw Open       Date:  2021-03-01

Review 10.  Management of Small Bowel Neuroendocrine Tumors.

Authors:  Vincent Larouche; Amit Akirov; Sameerah Alshehri; Shereen Ezzat
Journal:  Cancers (Basel)       Date:  2019-09-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.